Investors Warned: Class Action Lawsuit Against Altimmune, Inc. in Wake of Major Stock Drop

Investor Alert: Class Action Lawsuit Against Altimmune, Inc.

On September 8, 2025, Pomerantz LLP announced a class action lawsuit against Altimmune, Inc., trading on NASDAQ under the symbol ALT. This action follows concerning developments regarding the company's MASH trial results. The firm is reaching out to investors who have suffered losses on their investments in Altimmune to inform them of their rights and the upcoming deadlines.

Background on the Lawsuit

The class action lawsuit focuses on allegations of securities fraud and other unlawful business practices by Altimmune and some of its executive officers and directors. Investors who purchased or acquired Altimmune securities during the specified class period have until October 6, 2025, to request the court to appoint them as the Lead Plaintiff in this case. This highlights the legal ramifications affecting both the investors and the company regarding its conduct.

In a press release dated June 26, 2025, Altimmune disclosed the topline results from its Phase 2b trial, which evaluated Pemvidutide for treating MASH. Despite the company providing optimistic expectations prior to the announcement, the actual results reported a lack of statistical significance concerning the primary endpoint of fibrosis reduction. The press release suggested a positive trend, yet it fell short of benchmarks set out for the trial, which raised alarms about the firm’s reliability in reporting accurate information to its investors.

Stock Impact and Investor Reactions

Following the announcement of these disheartening results, Altimmune's stock saw a drastic dip, plummeting $4.10 per share (-53.2%), ending the day at $3.61 per share. This significant downturn served as a wake-up call for investors who were previously led to believe by the company that results would meet or exceed expectations. Importantly, this event has sparked many to question the integrity and transparency of Altimmune's practices, leading to increased scrutiny from regulatory bodies and the public alike.

Legal Options for Affected Investors

Investors impacted by Altimmune’s stock drop are encouraged to reach out to Pomerantz LLP for assistance. Danielle Peyton, lead attorney for this case, can be contacted via email or phone. It is essential for those who filed a class action to provide their mailing addresses, phone numbers, and details of shares purchased to ensure their interests are accounted for as this case progresses.

Pomerantz’s Commitment to Victims of Securities Fraud

Founded by Abraham L. Pomerantz, a pioneer in the class action arena, Pomerantz LLP has established itself as a leading law firm in corporate, securities, and antitrust class litigation. With offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has a strong track record of recovering significant damages for victims of securities fraud and other corporate misconduct. Over its 85-year history, Pomerantz has advocated for investors, ensuring their rights are protected against corporate breaches and fraudulent activities.

Investors should remain vigilant and take proactive measures if they believe they have been wronged. The class action against Altimmune serves as a reminder of the importance of corporate accountability and transparency in financial markets.

For further details about the class action lawsuit and the implications for investors, visit Pomerantz's official website.